Kingswood Wealth Advisors LLC Invests $40,000 in Altimmune, Inc. $ALT

Kingswood Wealth Advisors LLC bought a new position in Altimmune, Inc. (NASDAQ:ALT) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 10,400 shares of the company’s stock, valued at approximately $40,000.

Several other hedge funds and other institutional investors have also modified their holdings of ALT. GAMMA Investing LLC boosted its position in shares of Altimmune by 214.2% in the first quarter. GAMMA Investing LLC now owns 6,745 shares of the company’s stock worth $34,000 after buying an additional 4,598 shares during the period. Headland Capital LLC acquired a new stake in shares of Altimmune in the first quarter worth $50,000. Geneos Wealth Management Inc. acquired a new stake in shares of Altimmune in the first quarter worth $50,000. Keudell Morrison Wealth Management acquired a new stake in shares of Altimmune in the second quarter worth $63,000. Finally, E Fund Management Co. Ltd. boosted its position in shares of Altimmune by 20.3% in the first quarter. E Fund Management Co. Ltd. now owns 13,427 shares of the company’s stock worth $67,000 after buying an additional 2,268 shares during the period. Institutional investors and hedge funds own 78.05% of the company’s stock.

Altimmune Price Performance

NASDAQ ALT opened at $3.92 on Monday. Altimmune, Inc. has a fifty-two week low of $2.90 and a fifty-two week high of $11.16. The stock’s 50-day moving average is $3.72 and its two-hundred day moving average is $4.60. The company has a debt-to-equity ratio of 0.09, a current ratio of 20.44 and a quick ratio of 20.44. The firm has a market cap of $345.98 million, a P/E ratio of -3.32 and a beta of 0.07.

Altimmune (NASDAQ:ALT) last posted its earnings results on Tuesday, August 12th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.05. Altimmune had a negative return on equity of 62.63% and a negative net margin of 438,730.03%.The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.00 million. On average, analysts anticipate that Altimmune, Inc. will post -1.35 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Wall Street Zen raised Altimmune from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th. William Blair reiterated a “market perform” rating on shares of Altimmune in a report on Friday, June 27th. UBS Group cut their price objective on Altimmune from $26.00 to $24.00 and set a “buy” rating for the company in a report on Wednesday, August 13th. JMP Securities cut their price objective on Altimmune from $25.00 to $15.00 and set a “market outperform” rating for the company in a report on Thursday, July 10th. Finally, HC Wainwright reiterated a “buy” rating and set a $12.00 price objective on shares of Altimmune in a report on Friday. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $17.40.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.